Literature DB >> 24568663

Class switch recombination process in ataxia telangiectasia patients with elevated serum levels of IgM.

Payam Mohammadinejad1, Hassan Abolhassani, Asghar Aghamohammadi, Shabnam Pourhamdi, Sujal Ghosh, Bamdad Sadeghi, Rasoul Nasiri Kalmarzi, Anne Durandy, Arndt Borkhardt.   

Abstract

Ataxia telangiectasia (AT) is a rare primary immunodeficiency disorder with various clinical manifestations. Increased serum levels of IgM and recurrent infections, mainly sinopulmonary infections, can be the presenting feature in a number of AT patients and may be initially misdiagnosed as hyper-IgM (HIgM) syndrome. This study was designed to investigate class switch recombination (CSR) as a critical mechanism in B lymphocytes' maturation to produce different isotypes of antibody in response to antigen stimulation in AT cases with HIgM presentation. Quantitative IgE production after stimulation by IL-4 and CD40L was considered as an indicator for CSR function. We also compared their results with sex and age matched AT patients without HIgM presentation. We report four AT patients with recurrent infections during infancy and high serum levels of IgM. Laboratory evaluations revealed defective CSR while none of the three AT patients without HIgM presentation had a defect in the CSR process. The characterized defect in AT is a mutation in the ataxia telangiectasia mutated (ATM) gene. This gene may result in CSR defects due to impaired DNA break repair. A special association between AT and HIgM may indicate a new subgroup of AT patients according to their clinical phenotype and CSR condition.

Entities:  

Keywords:  ataxia telangiectasia; class switch recombination; hyper-IgM syndrome; α-feto protein

Mesh:

Substances:

Year:  2015        PMID: 24568663     DOI: 10.1080/15321819.2014.891525

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  6 in total

1.  A novel ATM mutation associated with elevated atypical lymphocyte populations, hyper-IgM, and cutaneous granulomas.

Authors:  Heather Minto; Kofi A Mensah; Paul R Reynolds; Eric Meffre; Kira Rubtsova; Erwin W Gelfand
Journal:  Clin Immunol       Date:  2019-01-09       Impact factor: 3.969

2.  Granulomatous Liver Disease in Ataxia-Telangiectasia With the Hyper-IgM Phenotype: A Case Report.

Authors:  Aleksandra Szczawińska-Popłonyk; Lidia Ossowska; Katarzyna Jończyk-Potoczna
Journal:  Front Pediatr       Date:  2020-11-19       Impact factor: 3.418

3.  Genetic Risk Variants for Class Switching Recombination Defects in Ataxia-Telangiectasia Patients.

Authors:  Parisa Amirifar; Mahya Mehrmohamadi; Mohammad Reza Ranjouri; Seyed Mohammad Akrami; Nima Rezaei; Ali Saberi; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2021-10-10       Impact factor: 8.542

4.  The natural history of ataxia-telangiectasia (A-T): A systematic review.

Authors:  Emily Petley; Alexander Yule; Shaun Alexander; Shalini Ojha; William P Whitehouse
Journal:  PLoS One       Date:  2022-03-15       Impact factor: 3.752

5.  Elevated IgM levels as a marker for a unique phenotype in patients with Ataxia telangiectasia.

Authors:  Alexander Krauthammer; Avishay Lahad; Lior Goldberg; Ifat Sarouk; Batia Weiss; Raz Somech; Michalle Soudack; Itai M Pessach
Journal:  BMC Pediatr       Date:  2018-06-04       Impact factor: 2.125

6.  Simple Measurement of IgA Predicts Immunity and Mortality in Ataxia-Telangiectasia.

Authors:  Stefan Zielen; Ruth Pia Duecker; Sandra Woelke; Helena Donath; Sharhzad Bakhtiar; Aileen Buecker; Hermann Kreyenberg; Sabine Huenecke; Peter Bader; Nizar Mahlaoui; Stephan Ehl; Sabine M El-Helou; Barbara Pietrucha; Alessandro Plebani; Michiel van der Flier; Koen van Aerde; Sara S Kilic; Shereen M Reda; Larysa Kostyuchenko; Elizabeth McDermott; Nermeen Galal; Claudio Pignata; Juan Luis Santos Pérez; Hans-Juergen Laws; Tim Niehues; Necil Kutukculer; Markus G Seidel; Laura Marques; Peter Ciznar; John David M Edgar; Pere Soler-Palacín; Horst von Bernuth; Renate Krueger; Isabelle Meyts; Ulrich Baumann; Maria Kanariou; Bodo Grimbacher; Fabian Hauck; Dagmar Graf; Luis Ignacio Gonzalez Granado; Seraina Prader; Ismail Reisli; Mary Slatter; Carlos Rodríguez-Gallego; Peter D Arkwright; Claire Bethune; Elena Deripapa; Svetlana O Sharapova; Kai Lehmberg; E Graham Davies; Catharina Schuetz; Gerhard Kindle; Ralf Schubert
Journal:  J Clin Immunol       Date:  2021-09-03       Impact factor: 8.317

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.